All Oncology News

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.

The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.

Innovative advances in personalized care, immunotherapy, and targeted treatment for people with many types of cancer were the focus of the inaugural Miami Precision Medicine Conference, held April 2 at the Ritz-Carlton in Fort Lauderdale.

The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.

Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.

Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.

Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.

Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.

With the aid of a $3.5 million National Institutes of Health grant, investigators from Rutgers Cancer Institute of New Jersey, along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

The treatment landscape continues to expand across non–small cell lung cancer, with the FDA approvals of multiple agents, including targeted therapies such as sotorasib and lorlatinib.

Two investigated doses of vibostolimab in combination with pembrolizumab resulted in comparable antitumor activity and safety in patients with locally advanced or metastatic cervical cancer who were naïve to PD-1/PD-L1 inhibitors, regardless of PD-L1 status.

The FDA has granted a breakthrough therapy designation to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer who have been previously treated with one ROS1 TKI and have not received prior platinum-based chemotherapy.

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

The anti-TIGIT immunotherapy tiragolumab in combination with atezolizumab did not improve progression-free survival over atezolizumab alone in the first-line treatment of patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

The hallmarks of lung cancer diagnosis and treatment are evolving, evidenced by increases in minimally invasive surgery, and immunotherapy combinations, as well as targeted therapies for rare molecular subsets.

The first-in-class, off-the-shelf therapeutic cancer vaccine VB10.16 in combination with atezolizumab generated positive responses in heavily pretreated patients with HPV16-positive advanced cervical cancer.

Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer

Rates of negative surgical margins and adequate lymphadenectomies were lower in Black patients with gastrointestinal tract cancer compared with White patients, according to data from a retrospective cohort study published in JAMA Network Open.

Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.

The American Cancer Society reported earlier this year that the risk of dying from cancer in the United States has decreased by 32% over the past 28 years, which translates to almost 3.5 million fewer cancer deaths.

Pembrolizumab plus concurrent chemoradiotherapy is being investigated as a potential therapy in patients with muscle-invasive bladder cancer.

Eric Liu, MD, FACS, reviews treatment options, pitfalls of diagnoses, and the importance of involving specialists and advocates early in neuroendocrine tumors.

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

Sajid A. Khan MD, FACS, FSSO, discusses findings from the study on racial disparities in surgical outcomes and quality of care for GI tract cancer, plus what issues need to be addressed to close the gap in care.

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.